Novartis AG ADR (NVS)vsStryker Corporation (SYK)
NVS
Novartis AG ADR
$161.93
+0.38%
HEALTHCARE · Cap: $303.67B
SYK
Stryker Corporation
$335.08
-2.75%
HEALTHCARE · Cap: $111.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 118% more annual revenue ($57.36B vs $26.30B). NVS leads profitability with a 17.5% profit margin vs 13.8%. SYK appears more attractively valued with a PEG of 1.37. SYK earns a higher WallStSmart Score of 57/100 (C).
NVS
Hold48
out of 100
Grade: D+
SYK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.93
$66.37 premium
Margin of Safety
-23.8%
Fair Value
$235.79
Current Price
$335.08
$99.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 20.3%
Generating 1.1B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.37 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
SYK carries more volatility with a beta of 0.78 — expect wider price swings.
SYK is growing revenue faster at 7.6% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SYK scores higher overall (57/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?